CEL-SCI CORPORATION "CEL-SCI Corporation's (NYSE: CVM): Bob's Best Buy Got Better!" Is Featured in Flaherty Financial Newsletter #52 as Patient Enrollment in Its Global Phase III Trial Booms
WEST HARRISON, NY / ACCESSWIRE / November 18, 2015 / A monthly record of 38 patients puts CEL-SCI Corporation (NYSE: CVM) , arguably the most undervalued Phase III biotech company, just 272 patients from its planned goal of enrolling 880 head and neck cancer patients in its global Phase III trial in 2016. This is the largest head and neck cancer patient trial in history with almost 100 sites in 24 countries including in U.S., Canada, Israel and parts of Europe and Asia.
CEL-SCI's unique goal is to prove that injecting its three week Multikine drug regime during the short window before surgery, radiation and/or chemotherapy will show at least a 10% improvement in overall patient survival. In contrast, other peer cancer immunotherapy companies, which require much longer treatment times, aim to boost the immune system after the tumor has recurred, when the immune system may have been debilitated by the toxicity from the earlier radiation and chemotherapy.
After a very slow start CEL-SCI is currently enrolling over one newly diagnosed cancer patient a day and picking up more momentum. Full enrollment of its trial is planned in 2016 with possible study completion in 2017. If the 10% improvement goal in patient survival is achieved with Multikine, CEL-SCI expects to submit a Biologics License Application to the FDA seeking approval of its Multikine drug regime. It could have the potential to become the fourth standard of care for head and neck cancer, joining surgery, chemotherapy and radiation.
Our complete in depth sponsored CEL-SCI Corporation profile can be found archived on our Flaherty Financial News website at http://www.flahertyfinancialnews.com/.
Direct Server Link to The Report - With the Modern Social Share Buttons: http://campaign.r20.constantcontact.com/render?ca=e0780ae8-3faa-44da-b903-e203d591ecf5&c=&ch
Direct Link to Flaherty Financial News Newsletter #52: http://archive.constantcontact.com/fs141/1101855435216/archive/1122899128905.html
About Flaherty Financial News Inc.
Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of interesting public companies. FFN was launched in 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers' Association, Bob is a co-founder of their annual student scholarship program and their annual award for significant long-term achievement in financial journalism.
About CEL-SCI Corporation.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy Multikine (Leukocyte Interleukin, injection) is currently being studied in a pivotal Phase III clinical trial as a potential neo-adjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care as compared to subjects treated with the current standard of care only is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multkine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA (Cooperative Research and Development Agreement).
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. The Company has operations in Vienna, Virginia and in and near Baltimore, Maryland.
Forward-Looking Statements:
This news release contains "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of l995) regarding the Flaherty Financial News Newsletter profile on CEL-SCI Corporation and its future business plans. These statements involve known and unknown risks and uncertainties, which may cause actual results and future achievements to be materially different than those implied by these forward-looking statements. Flaherty Financial News Inc. and CEL-SCI Corporation have and undertake no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in their expectations of future events. Our full disclaimer and safe harbor statement appears in our Flaherty Financial News Newsletter.
Contact:
Flaherty Financial News Inc.
Robert J. Flaherty, Editor and Chairman
Phone: (914) 831-1151
http://www.flahertyfinancialnews.com
SOURCE: Flaherty Financial News Inc.
